Biontech Se Sponsored Adr Stock News

26 More Cases Of Heart Inflammation Linked To Pfizer Jab Pfizer is already quietly scrambling Friday as the COVID "variant of the moment" raises new questions about the efficacy of its vaccine (while the latest "data" shows Merck may have oversold its mulnupiravir drug as a "miracle cure" for the virus), it appears 26 new cases of the rare side effect known as myocarditis have been reported during the week ending Nov. 21. There is also one new case of blood clots case linked to the AstraZeneca jab following receipt of the first dose. The new case increased the total Thrombosis with thrombocytopenia syndrome (TTS) or blood clots cases to 164 out of 13.4 million doses. Of these 148 (81 confirmed, 62 probable) related to a first dose of and 21 to a second dose (six confirmed, 15 probable). Eight people have died as a result of blood clots six of these were women. Put another way, myocarditis is reported in one to two in every 100,000 people who receive Pfizer. There have also been a total of 150 reports of suspected Guillain-Barre Syndrome (GBS) occurring after vaccination with AstraZeneca, a rare but sometimes serious immune disorder affecting the nerves.

FinancialBuzz.coms latest The Buzz Show: Featuring Our Corporate News Recap on BioNTech SE Surges after it and Pfizer Inc. Received Positive CHMP Opinion for Comirnaty in Children ages 5-12 BioNTech SE (NASDAQ: BNTX) climbed over 10% in premarket trading after the company and Pfizer Inc. received a positive CHMP Opinion on the administration of COMIRNATY® The post The Buzz Show: BioNTech SE (NASDAQ: BNTX) and Pfizer Receive Positive CHMP Opinion for Comirnaty first appeared on Financial Buzz .

During the recent session, BioNTech SE (NASDAQ:BNTX)s traded shares were 6.69 million. At the last check today, the stocks price was $366.67, reflecting an intraday gain of 20.31% or $61.91. The 52-week high for the BNTX share is $464.00, that puts it down -26.54 from that peak though still a striking 78.03% gain since the Is BioNTech SE (NASDAQ: BNTX) Stock On Course For Another Boom Or Bust? Read More »

BioNTech, AstraZeneca, and Johnson & Johnson have announced plans to test their vaccinations against the new variant of concern.

FRANKFURT: Germanys BioNTech said Friday it was urgently studying how well the coronavirus vaccine it developed with Pfizer protects against the new B.1.1.529 variant detected in South Africa. We expect more data from the laboratory tests in two weeks at the latest, a spokesperson said. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally. The discovery of the new variant by scientists in South Africa has sparked global alarm, amid concerns its many mutations could make it even more dangerous than the [] The post New variant impact data within 2 weeks first appeared on News Pakistan TV .

The post Pfizer-BioNTech investigating new Covid variant, J&J testing vaccine against it appeared on BitcoinEthereumNews.com . A vial of Pfizer-BioNTech Covid-19 vaccine. Getty Images Pfizer and BioNTech are investigating the new, heavily mutated variant of the virus that causes Covid-19, the companies said Friday morning. We

Pfizer and BioNTech said they expect more data from lab tests in two weeks at the latest.

Two new variants of COVID-19 which appear to have emerged in Southern Africa are raising extremely serious concerns around the world. The variantsknown as C.1.2 and B.1.1.529appear to have a worrisome combination of changes, including changes that could make them highly evasive of antibodies from both vaccines and previous infections. Of particular concern: these variants appear to be more contagious than the already highly infectious delta, with the B.1.1.529 variant in particular going from a small cluster of cases, to local dominance, almost overnight. The B.1.1.529 variant, which could gain the label nu following a World Health Organization meeting on Friday, is raising concerns great enough that both Israel and the U.K. have moved quickly to ban travel to and from the region where this variant has been identified. First identified in Botswana , the variant was initially tagged as a very small cluster (4 cases in Botswana, 77 in South Africa, and 1 case in Hong Kong). However, as virologist Tom Peacock of Imperial College quickly noted, the number of mutations seen in this variant are really awful and give it a horrific spike profile . Other variants showing extreme mutations on the spike protein have been identified before, and several of these have contained changes that suggested they could be more evasive of antibodies from existing vaccines and past infections.

It will take about two weeks to determine whether the widely used vaccine from Pfizer and BioNTech will work against the new strain of the coronavirus that has emerged in southern Africa. That is what a spokesperson for the German company BioNTech said. We expect more data from the lab tests in two weeks [] The post BioNTech: Effect of Vaccine Against Variant Clear in Two Weeks appeared first on INC News .

Germanys BioNTech said Friday it was urgently studying how well the coronavirus vaccine it developed with Pfizer protects against the new B.1.1.529 variant detected in South Africa. We expect more The post BioNTech/Pfizer expect new variant impact data within 2 weeks appeared first on Nigeria''s Top News Site .

The joint makers of the widely used Pfizer/BioNTech vaccine are assessing how effective their jab is against the new Covid-19 variant recently discovered in South Africa, according to the Reuters news agency. We understand the concern of experts and have immediately initiated investigations on variant B.1.1.529, Reuters quotes BioNTech as saying. The German company will []

Vaccine stocks Pfizer, BioNTech and Moderna popped Friday as scientists grappled with a new Covid variant first detected in South Africa.

NEW YORK , Nov. 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, BNTX, CARS, TDOC, and PFE. Full story available on Benzinga.com

Pfizer CEO Warns New Vaccine To Combat Heavily-Mutated Coronavirus Could Take 100 Days Several countries -- including Britain, France, Israel, Italy, and Singapore are moving fast to restrict travel from South Africa and other countries after a new coronavirus variant with mutations was discovered five days ago. The new variant is so concerning that Pfizer''s CEO confirmed a new vaccine would take more than three months to develop. According to a research note published by Citi analyst Andrew Baum, the Nu variant, referred to as B.1.1529, was discovered in Botswana with at least 100 confirmed cases in South Africa and detection in Israel and Hong Kong. We noted Friday morning Belgium, the first European country, has documented cases of the new strain. Baum said the next few weeks of testing would be essential to determine whether Nu is more aggressive than delta. Lab tests could conclude BioNTech, Pfizer would have to reformulate their vaccine. He noted one Hongkonger who was double Pfizer vaccinated experienced a breakthrough infection with Nu.

BioNTech and Pfizer said that experts are studying a new variant of coronavirus discovered in South Africa, more information is expected in two weeks